MAGE-A3-specific anticancer immunotherapy in the clinical practice

Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Brichard, Vincent G, Godechal, Quentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827067/
https://www.ncbi.nlm.nih.gov/pubmed/24244898
http://dx.doi.org/10.4161/onci.25995
Descripción
Sumario:Antigen-specific immunotherapy may offer a unique approach to fight cancer. We have demonstrated that specific immunotherapeutic regimens involving recombinant melanoma antigen family A3 (MAGE-A3) and different immunostimulants exert clinical anticancer activity. In particular, the combination of recombinant MAGE-A3 and AS15, a multicomponent immunostimulant, was found to elicit robust antigen-specific immune responses.

Ejemplares similares